M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Single Step Lesion Annotation and Localization of Suspicious Breast Lesions

Early Phase 1

Recruiting

Conditions: Breast Lesions

Interventions: Device: SAVI Scout®

First Posted Date: 2021-11-11

Last Posted Date: 2024-07-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT05118295

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Phase 2

Active, not recruiting

Conditions: High Grade Fallopian Tube Serous Adenocarcinoma
High Grade Ovarian Serous Adenocarcinoma
Peritoneal High Grade Serous Adenocarcinoma
Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
Recurrent High Grade Ovarian Serous Adenocarcinoma
Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma

Interventions: Drug: Lenvatinib
Biological: Pembrolizumab

First Posted Date: 2021-11-10

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05114421

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Phase 1

Active, not recruiting

Conditions: Myeloid Malignancies
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Mesna
Drug: Fludarabine phosphate
Drug: Cyclophosphamide
Drug: Melphalan
Drug: Filgrastim
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Drug: Total Body Irradiation One Dose

First Posted Date: 2021-11-10

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05115630

Locations: 🇺🇸
M D Anderson Caner Center, Houston, Texas, United States

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Phase 1

Recruiting

Conditions: Hematological Malignancy

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Drug: CAR.5/IL15-transduced CB-NK cells

First Posted Date: 2021-11-08

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT05110742

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies

Active, not recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Electronic Health Record Review

First Posted Date: 2021-11-05

Last Posted Date: 2024-08-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 170

Registration Number: NCT05108519

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic

Active, not recruiting

Conditions: COVID-19 Infection
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Procedure: Discussion
Other: Best Practice
Other: Questionnaire Administration

First Posted Date: 2021-11-01

Last Posted Date: 2024-10-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 107

Registration Number: NCT05102656

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Phase 1

Recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
JC Virus Infection
BK Virus Infection
Symptomatic COVID-19 Infection Laboratory-Confirmed
Adenovirus Infection
Cytomegaloviral Infection
Malignant Solid Neoplasm

Interventions: Biological: Virus-specific Cytotoxic T-lymphocytes

First Posted Date: 2021-11-01

Last Posted Date: 2024-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05101213

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

Phase 3

Withdrawn

Conditions: Thoracic
Pulmonary Disease

Interventions: Other: Placebo
Drug: Gabapentin

First Posted Date: 2021-10-29

Last Posted Date: 2023-04-13

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05100160

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

Phase 2

Recruiting

Conditions: Merkel Cell Carcinoma

Interventions: Drug: Radiation therapy

First Posted Date: 2021-10-29

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT05100095

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center

Not yet recruiting

Conditions: Metastatic Malignant Solid Neoplasm

Interventions: Procedure: Discussion
Other: Electronic Health Record Review
Other: Questionnaire Administration

First Posted Date: 2021-10-27

Last Posted Date: 2024-03-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT05095948

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy